Biogen to acquire gene therapy company Nightstar Therapeutics for $800M
The biotech company said the deal would allow it to strengthen its ophthalmology pipeline. It follows last week's acquisition of Spark Therapeutics by Roche for $4.8 billion.
choroideremia